Cetuximab Intravenous and Trifluoperazine Hydrochloride

• Generic Name: cetuximab
• Dosage Forms: n.a.
• Other Brand Names: Erbitux

Cetuximab injection is used together with radiation treatment for advanced squamous cell carcinoma of the head and neck (SCCHN), or with a platinum-based cancer medicine with fluorouracil to treat SCCHN that has come back (recurrent) or has spread to other parts of the body (metastatic). Cetuximab injection is also used alone in patients with recurrent or metastatic SCCHN who have received other medicines that did not work well.

Cetuximab injection is used together with other medicines (eg, irinotecan, fluorouracil, leucovorin) to treat K-Ras wild-type, epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer (mCRC). Your doctor will test for the presence of this gene mutation. Cetuximab injection is also used alone to treat patients with mCRC who have received other medicines (eg, irinotecan, oxaliplatin) that did not work well.

Cetuximab interferes with the growth of cancer cells, which are then destroyed by the body. Since the growth of normal body cells may also be affected by cetuximab, other effects will also occur. Some of these may be serious and must be reported to your doctor. Other effects, such as a skin rash, may not be serious but may cause concern. Some effects do not occur until months or years after the medicine is used.

Before you begin treatment with cetuximab, you and your doctor should talk about the benefits of cetuximab as well as the risks of using it.

Cetuximab should only be given by or under the direct supervision of your doctor.

• Generic Name: trifluoperazine
• Dosage Forms: n.a.
• Other Brand Names: Stelazine

Treatment of schizophrenia.

American Psychiatric Association (APA) considers most atypical antipsychotic agents first-line drugs for management of the acute phase of schizophrenia (including first psychotic episodes). APA considers conventional antipsychotic agents first-line in patients with acute psychotic episodes who have been treated successfully in the past with, or who prefer, conventional agents.

Patients who do not respond to or tolerate one drug may be successfully treated with an agent from a different class or with a different adverse effect profile.

Short-term management of nonpsychotic anxiety in patients with generalized anxiety disorder.

Not established whether trifluoperazine is useful for the management of other nonpsychotic conditions in which anxiety or manifestations that mimic anxiety are evident (e.g., physical illness, organic mental conditions, agitated depression, character pathologies).

Because of the risks of toxicity, use only as an alternative to other less toxic anxiolytic agents (e.g., benzodiazepines) in most patients.

Efficacy not established for the management of behavioral complications in patients with mental retardation.